BACKGROUND: Patients with ulcerative colitis are at increased risk for developing colorectal cancer. We have shown that Toll-like receptor-4 (TLR4) is overexpressed in human colitis-associated cancer (CAC) and that mice deficient in TLR4 are markedly protected against colitis-associated neoplasia. We wished to elucidate the specific contributions of TLR4 signaling by myeloid cells and colonic epithelial cells (CEC) in colitis-associated tumorigenesis. METHODS: TLR4-deficient mice or wildtype littermates (WT) were transplanted with bone marrow (BM) cells: TLR4(-/-) BM-->WT mice (TLR4-expressing CEC) and WT BM-->TLR4(-/-) mice (TLR4-expressing myeloid cells). Colitis-associated neoplasia was induced by azoxymethane (AOM 7.3 mg/kg) injection and 2 cycles of dextran sodium sulfate (DSS) treatment. RESULTS: The number and size of dysplastic lesions were greater in TLR4(-/-) BM-->WT mice than in WT BM-->TLR4(-/-) mice (P < 0.005). Histologically, TLR4(-/-) BM-->WT mice had greater numbers of mucosal neutrophils and macrophages compared to WT BM-->TLR4(-/-) mice. The chemokines KC and CCL2, important in recruitment of neutrophils and macrophages, respectively, were induced in mice expressing TLR4 in CEC rather than the myeloid compartment. The lamina propria infiltrate of mice expressing TLR4 in CEC was characterized by macrophages expressing Cox-2. Moreover, mice expressing TLR4 in CEC rather than the myeloid compartment had increased production of amphiregulin and EGFR activation. CONCLUSIONS: These findings indicate that TLR4 signaling on CEC is necessary for recruitment and activation of Cox-2-expressing macrophages and increasing the number and size of dysplastic lesions. Our results implicate innate immune signaling on CEC as a key regulator of a tumor-promoting microenvironment.
BACKGROUND:Patients with ulcerative colitis are at increased risk for developing colorectal cancer. We have shown that Toll-like receptor-4 (TLR4) is overexpressed in humancolitis-associated cancer (CAC) and that mice deficient in TLR4 are markedly protected against colitis-associated neoplasia. We wished to elucidate the specific contributions of TLR4 signaling by myeloid cells and colonic epithelial cells (CEC) in colitis-associated tumorigenesis. METHODS:TLR4-deficientmice or wildtype littermates (WT) were transplanted with bone marrow (BM) cells: TLR4(-/-) BM-->WT mice (TLR4-expressing CEC) and WT BM-->TLR4(-/-) mice (TLR4-expressing myeloid cells). Colitis-associated neoplasia was induced by azoxymethane (AOM 7.3 mg/kg) injection and 2 cycles of dextran sodium sulfate (DSS) treatment. RESULTS: The number and size of dysplastic lesions were greater in TLR4(-/-) BM-->WT mice than in WT BM-->TLR4(-/-) mice (P < 0.005). Histologically, TLR4(-/-) BM-->WT mice had greater numbers of mucosal neutrophils and macrophages compared to WT BM-->TLR4(-/-) mice. The chemokines KC and CCL2, important in recruitment of neutrophils and macrophages, respectively, were induced in mice expressing TLR4 in CEC rather than the myeloid compartment. The lamina propria infiltrate of mice expressing TLR4 in CEC was characterized by macrophages expressing Cox-2. Moreover, mice expressing TLR4 in CEC rather than the myeloid compartment had increased production of amphiregulin and EGFR activation. CONCLUSIONS: These findings indicate that TLR4 signaling on CEC is necessary for recruitment and activation of Cox-2-expressing macrophages and increasing the number and size of dysplastic lesions. Our results implicate innate immune signaling on CEC as a key regulator of a tumor-promoting microenvironment.
Authors: Masayuki Fukata; Kathrin S Michelsen; Rajaraman Eri; Lisa S Thomas; Bing Hu; Katie Lukasek; Cynthia C Nast; Juan Lechago; Ruliang Xu; Yoshikazu Naiki; Antoine Soliman; Moshe Arditi; Maria T Abreu Journal: Am J Physiol Gastrointest Liver Physiol Date: 2005-05 Impact factor: 4.052
Authors: Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes Journal: Gastroenterology Date: 2004-02 Impact factor: 22.682
Authors: S Hauptmann; G Zwadlo-Klarwasser; P Hartung; B Klosterhalfen; C J Kirkpatrick; C Mittermayer Journal: Pathol Res Pract Date: 1994-02 Impact factor: 3.250
Authors: Hongxia Z Imtiyaz; Emily P Williams; Michele M Hickey; Shetal A Patel; Amy C Durham; Li-Jun Yuan; Rachel Hammond; Phyllis A Gimotty; Brian Keith; M Celeste Simon Journal: J Clin Invest Date: 2010-07-19 Impact factor: 14.808
Authors: K K Gkouskou; M Ioannou; G A Pavlopoulos; K Georgila; A Siganou; G Nikolaidis; D C Kanellis; S Moore; K A Papadakis; D Kardassis; I Iliopoulos; F A McDyer; E Drakos; A G Eliopoulos Journal: Oncogene Date: 2015-08-17 Impact factor: 9.867
Authors: Israel Vlodavsky; Phillip Beckhove; Immanuel Lerner; Claudio Pisano; Amichai Meirovitz; Neta Ilan; Michael Elkin Journal: Cancer Microenviron Date: 2011-08-03
Authors: Chhinder P Sodhi; Xia-Hua Shi; Ward M Richardson; Zachary S Grant; Richard A Shapiro; Thomas Prindle; Maria Branca; Anthony Russo; Steven C Gribar; Congrong Ma; David J Hackam Journal: Gastroenterology Date: 2009-09-26 Impact factor: 22.682
Authors: Masayuki Fukata; Limin Shang; Rebeca Santaolalla; John Sotolongo; Cristhine Pastorini; Cecilia España; Ryan Ungaro; Noam Harpaz; Harry S Cooper; Greg Elson; Marie Kosco-Vilbois; Julia Zaias; Maria T Perez; Lloyd Mayer; Arunan S Vamadevan; Sergio A Lira; Maria T Abreu Journal: Inflamm Bowel Dis Date: 2010-11-15 Impact factor: 5.325
Authors: Ibrahim Altamemi; E Angela Murphy; James F Catroppo; Elizabeth E Zumbrun; Jiajia Zhang; Jamie L McClellan; Udai P Singh; Prakash S Nagarkatti; Mitzi Nagarkatti Journal: J Pharmacol Exp Ther Date: 2014-05-09 Impact factor: 4.030